Fluvoxamine Extended-release

— THERAPEUTIC CATEGORIES —
  • Anxiety/OCD

Fluvoxamine Extended-release Generic Name & Formulations

General Description

Fluvoxamine maleate 100mg, 150mg; ext-rel caps.

Pharmacological Class

SSRI.

How Supplied

Contact supplier

Fluvoxamine Extended-release Indications

Indications

Obsessive-compulsive disorder.

Fluvoxamine Extended-release Dosage and Administration

Adult

Swallow whole. ≥18yrs: initially 100mg once daily at bedtime; may increase in 50mg increments at 1-week interval; range 100–300mg/day; max 300mg/day. Elderly, hepatic impairment: initially 100mg and titrate slowly.

Children

Not established.

Fluvoxamine Extended-release Contraindications

Contraindications

Concomitant alosetron, tizanidine, pimozide, thioridazine, ramelteon. During or within 14 days of MAOIs; do not start an MAOI during or within 14 days of fluvoxamine. Concomitant linezolid, IV methylene blue.

Fluvoxamine Extended-release Boxed Warnings

Boxed Warning

Suicidality and antidepressants.

Fluvoxamine Extended-release Warnings/Precautions

Warnings/Precautions

Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor for clinical worsening or unusual changes. Screen for bipolar disorder. Monitor for serotonin syndrome; discontinue if occurs. History of seizures (discontinue if occurs), mania/hypomania. ECT. Cardiovascular disease. Liver dysfunction. Risk for bleeding events. Angle-closure glaucoma. Conditions that affect metabolism or hemodynamic response. Hyponatremia (esp. in elderly). Sexual dysfunction. Reduced activity of CYP2D6. Reevaluate periodically. Write ℞ for smallest practical amount. Avoid abrupt cessation. Elderly. Labor & delivery. Pregnancy (esp. during 3rd trimester). Nursing mothers: monitor infants.

Fluvoxamine Extended-release Pharmacokinetics

See Literature

Fluvoxamine Extended-release Interactions

Interactions

See Contraindications. Prolongation of QT interval with pimozide, thioridazine. Avoid alcohol. Increased risk of serotonin syndrome with other serotonergic drugs (eg, other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue); monitor. Potentiates diazepam (not recommended), triazolam and alprazolam (reduce their doses by at least ½), midazolam, theophylline (reduce its dose by ⅔ and monitor), warfarin, carbamazepine, tricyclic antidepressants (reduce their doses and monitor), propranolol, metoprolol (reduce their doses), clozapine, methadone, tacrine. Caution with drugs that inhibit CYP2D6 (eg, quinidine) or CYP3A4, phenytoin, diltiazem. Increased risk of bleeding with concomitant NSAIDs, aspirin, warfarin, and others that affect coagulation. Monitor mexiletine levels. Smokers may have increased metabolism.

Fluvoxamine Extended-release Adverse Reactions

Adverse Reactions

Abnormal ejaculation, anorexia, anorgasmia, asthenia, diarrhea, nausea, somnolence, sweating, tremor, anxiety, decreased libido, myalgia, pharyngitis, vomiting, dyspepsia, dizziness, insomnia, yawning.

Fluvoxamine Extended-release Clinical Trials

See Literature

Fluvoxamine Extended-release Note

Notes

Formerly known under the brand name Luvox CR.

Fluvoxamine Extended-release Patient Counseling

See Literature